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Abstract
Nitric oxide (NO) has been strongly implicated in glioma progression and angiogenesis. The endogenous inhibitors of NO 
synthesis, asymmetric dimethylarginine (ADMA) and N-monomethyl-l-arginine (l-NMMA), are metabolized by dimethyl-
arginine dimethylaminohydrolase (DDAH), and hence, DDAH is an intracellular factor that regulates NO. However, DDAH 
may also have an NO-independent action. We aimed to investigate whether DDAH I has any direct role in tumour vascular 
development and growth independent of its NO-mediated effects, in order to establish the future potential of DDAH inhibi-
tion as an anti-angiogenic treatment strategy. A clone of rat C6 glioma cells deficient in NO production expressing a pTet 
Off regulatable element was identified and engineered to overexpress DDAH I in the absence of doxycycline. Xenografts 
derived from these cells were propagated in the presence or absence of doxycycline and susceptibility magnetic resonance 
imaging used to assess functional vasculature in vivo. Pathological correlates of tumour vascular density, maturation and 
function were also sought. In the absence of doxycycline, tumours exhibited high DDAH I expression and activity, which 
was suppressed in its presence. However, overexpression of DDAH I had no measurable effect on tumour growth, vessel 
density, function or maturation. These data suggest that in C6 gliomas DDAH has no NO-independent effects on tumour 
growth and angiogenesis, and that the therapeutic potential of targeting DDAH in gliomas should only be considered in the 
context of NO regulation.
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Introduction
Angiogenesis is an important driver of the growth and devel-
opment of solid tumours. Several angiogenic stimuli also 
induce the production of nitric oxide (NO). Strong positive 
correlations between the expression of nitric oxide synthases 
(NOS) and tumour progression have been identified in a 
number of human cancers [1]. Intracellular factors which 
regulate NO synthesis may therefore represent important 
targets in the control of tumour growth and vascularization.
The synthesis of NO can be modulated by the two dimeth-
ylarginine dimethylaminohydrolase (DDAH) isoforms via 
the asymmetric dimethylarginine (ADMA) pathway [2]. 
DDAH enzymes catalyse the hydrolysis of methylarginines, 
ADMA and N-monomethyl-l-arginine (l-NMMA), to citrul-
line and either dimethylamine or methylamine, respectively 
[3]. ADMA and l-NMMA are endogenous, competitive 
inhibitors of all three NOS isoforms, and NO production is 
physiologically regulated by methylarginines [4].
DDAH activity has been detected in various human 
tumours including those arising in the brain; astrocytomas in 
particular exhibited high levels of DDAH activity [5]. High 
expression of DDAH I has also been observed in aggres-
sive triple-negative breast cancer cell lines, where DDAH 
I was a key regulator of cell migration and vasculogenic 
mimicry [6]. Overexpression of DDAH I has been shown 
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to increase NO production and enhance tumour growth and 
angiogenesis in C6 gliomas in vivo [7, 8]. Pharmacological 
manipulation of DDAH may be an attractive therapeutic tar-
get for regulating NO in cancer. DDAH inhibitors can help 
overcome one of the major considerations for NO-focused 
therapies, which is targeting pathological NO production 
while sparing beneficial NO produced constitutively. Direct 
non-selective NOS inhibitors can lead to inherent adverse 
effects by limiting the NO antimicrobial properties or by 
inhibiting the constitutive NOS isoforms [9].
Previous studies have looked into DDAH-mediated NO-
dependent effects on tumour vascularization. However, other 
studies have also suggested that DDAH and/or ADMA can 
exert direct, NO-independent effects on angiogenesis. For 
example, DDAH II overexpression led to increased vascular 
endothelial growth factor (VEGF) expression in endothe-
lial cells by binding to protein kinase A (PKA), increasing 
phosphorylation and activation of the transcription factor 
Sp1 [10, 11]. These studies imply that the DDAH/ADMA 
pathway may directly regulate tumour angiogenesis. We can 
hypothesize that if DDAH has NO-independent effects, then 
it might be a better anti-cancer target than NO synthases, as 
NO operates in a bimodal fashion in cancer and can be both 
pro- and anti-tumorigenic, depending on its concentration 
and the tumour microenvironment [12, 13].
To investigate whether there are any NO-independent 
effects of tumour-derived DDAH I on tumour angiogenesis, 
we first identified a C6-derived glioma cell line deficient 
in NO production, and genetically modified it to overex-
press DDAH I under doxycycline (DOX) regulation. These 
cells were then characterized and compared against paren-
tal and wild-type cells in vitro. Subsequently, the vascular 
phenotype of tumours derived from the regulatable cells 
was compared in the presence or absence of DOX and with 
tumours derived from constitutive DDAH I overexpressing 
NO-producing C6 cells. The vascular functionality of these 
tumours was interrogated in vivo using quantitative non-
invasive MRI, and ex vivo histopathological analysis.
Materials and methods
Cell culture
Both wild-type and transfected C6 rat glioma cells (Euro-
pean Collection of Cell Cultures, Salisbury, UK) were main-
tained in Nutrient Ham’s F-10 (Sigma-Aldrich, Dorset, UK) 
medium containing 2 mM l-glutamine, 100 U/ml penicillin, 
0.2 mg/ml streptomycin and 10% (v/v) tetracycline-free fetal 
bovine serum (Clontech, Saint-Germain-en-Laye, France).
To achieve inducible overexpression of DDAH I, C6 
wild-type (wt) cells were engineered to include a DDAH 
I cDNA sequence combined with a tetracycline-inducible 
system (pTet Off), which allowed gene expression to be con-
trolled by tetracycline, or as in our study, by its water solu-
ble derivative, DOX. Briefly, C6 cells transfected with the 
pRevTet-Off-IN vector (Clontech), referred to as C6 paren-
tal (par) cells, were kindly provided by Prof. M. Neeman 
(Weizmann Institute of Science, Rehovot, Israel). These cells 
were selected for this study as they did not express iNOS 
and produced limited NO. Full length rat DDAH I cDNA 
(previously generated by Kostourou et al. [5]) was cloned 
into the BamHI site of the pTRE2hyg plasmid (Clontech) 
to generate pTRE2hyg.DDAHI. C6 par cells were trans-
fected with the pTRE2hyg.DDAHI vector using Fugene 6 
and selection was performed with 500 µg/ml hygromycin B 
in the culture medium in the presence of 1 µg/ml DOX. The 
stably transfected clone (designated C6 DDAH) with the 
highest DDAH I overexpression in the absence of DOX was 
chosen for further experimentation, and grown in the pres-
ence or absence of 2 µg/ml DOX. Table 1 lists all the cell 
lines and tumour types used in the present study and their 
main characteristics.
Nitric oxide production
Cells were stimulated with cytokines (10 ng/ml TNF-α, 
1000 U/ml IFN-γ) and 5 µg/ml LPS. Nitrite and nitrate pro-
duction provided a proxy measure of NO synthesis. Nitrate 
was reduced to nitrite using vanadium chloride, and the total 
nitrate plus nitrite (NOx) determined using the Griess reac-
tion [14, 15]. All experiments were performed in triplicate.
Western blot analysis
The protein concentration of cell lysates and tumour 
homogenates was determined using the Bradford assay [16] 
and equal amounts of protein were analysed by SDS-PAGE. 
DDAH I and iNOS expression were detected using goat 
polyclonal anti-mouse/rat DDAH I antibodies and rabbit 
polyclonal anti-mouse/rat iNOS antibodies (M-19; sc-650, 
Santa Cruz, Heidelberg, Germany) respectively. Polyclonal 
anti-α-actin antibodies (Sigma-Aldrich) or polyclonal anti-
α-tubulin antibodies (Sigma-Aldrich) were used to verify 
equal protein loading. The integrated density of the indi-
vidual bands for iNOS and DDAH I was measured and cor-
rected using the integrated density of the individual bands 
for either α-actin or α-tubulin using ImageJ software [17].
DDAH activity assay
DDAH I activity was determined by measuring the conver-
sion of ADMA to l-citrulline [18]. Lyophilized cells (200 µg 
protein) were mixed with 20 µl 4 mM ADMA in phosphate-
buffered saline (PBS, pH 6.5) and incubated for 4 h at 37 °C. 
The enzymatic reaction was stopped using an equal volume 
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of 10% (w/v) trichloroacetic acid. Samples were centrifuged 
and the supernatants were mixed with a 2:1 ratio mixture of 
antipyrine (0.5% (w/v) in 50% sulphuric acid) and diacetyl 
monoxime (0.8% (w/v) in 5% acetic acid). Subsequently, 
samples were heated in a boiling water bath for 30 min 
and the amount of l-citrulline formed was determined by 
measuring the absorbance at 466 nm. To detect DDAH I 
activity in tumours, tumour homogenates (400 µg of protein) 
were initially incubated with 4 µl of 2500 U/ml Urease from 
Canavalia ensiformis for 20 min at 37 °C in order to elimi-
nate excess urea [19]. Subsequently, samples were mixed 
with 25 µl 4 mM ADMA substrate in PBS and incubated 
for 20 h at 37 °C. The rest of the assay was performed in a 
similar manner as for the lysed cells. The enzymatic activity 
was corrected for protein concentration.
VEGF ELISA
VEGF concentration was measured in cell culture medium, 
collected from confluent 3 cm dishes 72 h after seeding, and 
in tumour homogenates using a rat VEGF ELISA kit (Pep-
roTech, London, UK) according to manufacturer’s instruc-
tions. Values were normalized to protein concentration.
Animals and tumours
Experiments were performed in accordance with the local 
ethical review panel, the UK Home Office Scientific Pro-
cedures Act 1986 and the UK National Cancer Research 
Institute Guidelines for the Welfare and Use of Animals in 
Cancer Research [20]. Female (7–8 weeks old) NCr nude 
mice were injected subcutaneously in the flanks with 2 × 106 
cells in 0.1 ml PBS. Tumour volume was calculated using 
the ellipsoid shape formula: (π/6) × Length × Width × Depth. 
Tumour doubling times (TDT) were calculated based on the 
individual tumour growth curves on a logarithmic plot using 
the formula: TDT = ln(2)/[slope of growth curve]. Prior to 
implantation, C6 DDAH cells were pre-treated for 5 days 
with DOX (C6 DDAH group A) or were grown in nor-
mal medium without DOX (C6 DDAH group B). Animals 
injected with C6 DDAH cells (groups A and B) were given 
drinking water containing 5% (w/v) sucrose with or without 
0.2 mg/ml DOX (n = 6 per group) (C6 DDAH ± DOX group 
A and C6 DDAH ± DOX group B). Additional animals 
(n = 4) were injected with constitutively DDAH I overex-
pressing cells (clone D27), previously engineered and char-
acterized by Kostourou et al [5].
Table 1  List of cell lines and tumours used in the present study and their main characteristics
In vitro experiments
Cell line name C6 wt C6 parental C6 DDAH
Description Wild-type C6 cells C6 cells with pTet-Off 
element (parental to C6 
DDAH cells)
DOX-inducible DDAH I overexpressing C6 cells
DOX Independent Independent Absence (− DOX) Presence (+ DOX)
DDAH I expres-
sion
Low endogenous expression Low endogenous expression Overexpression Low endogenous expression
NO production Increased by cytokines Negligible (cytokine inde-
pendent)
Negligible (cytokine inde-
pendent)
Negligible (cytokine inde-
pendent)
VEGF expression Endogenous Endogenous Low Low
In vivo experiments
Tumour type C6 DDAH group A (from cells grown in normal 
medium)
C6 DDAH group B (from cells grown in 
medium with DOX)
D27
Description DOX-inducible DDAH I overexpressing C6 
cells
DOX-inducible DDAH I overexpressing C6 
cells
Constitutively DDAH 
I overexpressing C6 
cells
DOX Absence (− DOX) Presence (+ DOX) Absence (− DOX) Presence (+ DOX) Independent
DDAH I expres-
sion
Overexpression Low endogenous 
expression
Overexpression Low endogenous 
expression
Overexpression
NO production Negligible Negligible Negligible Negligible High
VEGF expression Low Low Low Low Very high
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Magnetic resonance imaging
Mice bearing size-matched (~ 500  mm3) tumours were 
anaesthetised with a 10 ml/kg intraperitoneal injection of 
Hypnorm (0.315 mg/ml fentanyl citrate plus 10 mg/ml flu-
anisone; Janssen Pharmaceutical, Wantage, UK), Hypnovel 
(5 mg/ml midazolam; Roche, West Sussex, UK) and water 
(1:1:2), and positioned so the tumour hung within a three-
turn 25-mm-diameter surface coil for MRI using a 4.7 T 
Varian Unity INOVA horizontal small-bore imaging system. 
The mouse core temperature was maintained at 37 °C using 
heated air blown through the magnet bore. Blood oxygen 
saturation was monitored using a MouseOx Pulse Oximeter 
(Braintree Scientific, MA, US).
T2-weighted spin echo images were acquired from seven 
axial 1-mm-thick slices positioned across the whole tumour, 
using a repetition time (TR) of 1500 ms, an echo time (TE) 
of 30 ms, and a 128 × 128 matrix over a 2.56-cm field of 
view. Intrinsic susceptibility MRI was performed to assess 
vessel function and maturation, utilizing carbogen (95% 
 O2/5%  CO2) breathing to increase blood oxygenation and 
localised vascular smooth muscle dilation. The changes in 
the tumour transverse relaxation rate R2*  (s−1) caused by 
perturbations in the paramagnetic deoxyhaemoglobin in the 
blood vessels were measured using a multi-gradient echo 
(MGRE) sequence. MGRE images were acquired from seven 
slices with TR of 450 ms, TE of 7–56 ms, an echo spacing 
of 7 ms and flip angle (α) of 45° during air and following a 
5-min transition period during carbogen (95%  O2/5%  CO2) 
breathing [21–23].
Susceptibility contrast MRI was then performed to 
quantify the tumour fractional blood volume (fBV, %). 
MGRE images were acquired, 5 min after air breathing was 
resumed, prior to and 5 min after intravenous injection of 
5.2 mgFe/kg of the ultrasmall superparamagnetic iron oxide 
(USPIO) contrast agent ferumoxtran (Guerbet S.A., Ville-
pinte, France). USPIO particles were used as a blood pool 
contrast agent that creates magnetic susceptibility variations 
close to blood vessels leading to an increase in water R2* in 
the surrounding tissue [24].
MRI data analysis
R2* maps were calculated on a voxel-by-voxel basis from 
MGRE image data using ImageJ and Matlab. Average 
apparent R2* relaxation rates were calculated for each slice 
for a region of interest (ROI), defined from the associated 
 T2-weighted image, encompassing the whole tumour but 
excluding the surrounding skin and muscle. Carbogen-
induced changes in  R2* (ΔR2*CB = R2*carbogen − R2*air) 
were determined over the whole tumour. Tumour fBV was 
determined over the same ROI from the increase in  R2* 
(ΔR2*USPIO = R2*post−USPIO − R2*pre−USPIO) caused by the 
USPIO particles as previously described [24, 25].
Histological analysis and microscopy
Following the MRI, mice were administered intraperito-
neally with 60 mg/kg of the hypoxia marker pimonidazole 
hydrochloride (Hypoxyprobe, Burlington, MA, USA) in 
PBS. After 45 min, mice were also injected intravenously 
with 15 mg/kg of the perfusion marker Hoechst 33342 
(Sigma-Aldrich, Dorset, UK) in PBS. Tumours were 
excised after 1 min and snap-frozen. For each tumour, 
three acetone-fixed cryosections (10 µm) were visualized 
for uptake of Hoechst 33342 by fluorescence microscopy 
using a motorized scanning stage (Prior Scientific Instru-
ments, Cambridge, UK) attached to a BX51 microscope 
(Olympus Optical, London, UK) driven by CellP (Soft 
Imaging System, Munster, Germany) to record composite 
digital images of whole tumour sections. The same sec-
tions were then processed for pimonidazole adduct forma-
tion using Hypoxyprobe-1 plus FITC-conjugated mouse 
monoclonal antibodies and imaged using the same stage 
coordinates. To assess endothelial and perivascular cell 
content, additional sections were stained with rat mono-
clonal anti-mouse CD31 antibodies [MEC 7.46] (ab7388, 
Abcam, Cambridge, UK), biotinylated goat anti-rat immu-
noglobulins (IgG) (Vector Laboratories, Peterborough, 
UK) and Fluorescein Avidin D (Vector Laboratories), 
and with rabbit polyclonal antibodies against smooth 
muscle actin (α-SMA, ab5694, Abcam) and Alexa-Fluor 
546 goat anti-rabbit secondary antibodies. The cell nuclei 
were counterstained with DAPI (4′,6-diamidino-2-phe-
nylindole). Non-immune mouse and rabbit IgG antibod-
ies were used in the same concentration with CD31 and 
α-SMA antibodies respectively as negative isotype con-
trols. Composite images were acquired using fluorescence 
microscopy as previously described [26]. Tumour sections 
were also stained with haematoxylin and eosin (H&E), and 
composite images were acquired under light microscopy.
Post-processing was performed on composite digital 
images using ImageJ software [17]. ROIs of whole tumour 
sections were defined and fluorescent particles detected 
above a constant colour threshold across all sections, which 
was higher than background fluorescence defined from iso-
type control stained tumour sections. The area of the tumour 
section with fluorescence was determined and expressed as a 
percentage of the whole tumour section, and for each tumour 
the average across three slices was determined. ROIs were 
also drawn around all necrotic foci on H&E-stained sections 
and necrosis was expressed as a percentage averaged across 
three tumour slices for each tumour.
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Statistical analysis
Data were analysed using GraphPad Prism (GraphPad 
Software Inc., La Jolla, CA, USA). Results are presented 
as mean ± 1 standard error of the mean (SEM) with signifi-
cance testing at a 5% confidence level. Student’s unpaired 
t-test was used to compare two groups and repeated meas-
ures ANOVA with Bonferroni’s Multiple Comparison post-
test was used to compare multiple groups.
Results
NO production is limited in C6 DDAH cells
Initial experiments confirmed that the basal production 
of NO by C6 parental cells was negligible and that they 
did not express iNOS in response to combined stimulation 
with cytokines and LPS (cytokine independent). As antic-
ipated, iNOS expression was also unaffected by cytokine 
and LPS stimulus and production of NOx was low in C6 
DDAH cells, which were derived from the selected C6 
parental cells. In contrast, cytokine stimulation of C6 
wild-type cells led to increased iNOS protein expression 
(2.3-fold) and NOx production (Fig. 1a, b; Table 1). The 
presence of DOX did not affect iNOS expression or NO 
synthesis in the C6 wt, C6 par or C6 DDAH cell lines.
DDAH I overexpression occurs in the absence of DOX 
in C6 DDAH cells
Expression of DDAH I protein was low (endogenous expres-
sion) in C6 wild-type and C6 parental cells and expression 
remained unaffected by the presence of DOX (Fig.  1c; 
Table 1). C6 DDAH cells exhibited a tight in vitro regulation 
of DDAH I expression with DOX. In the absence of DOX, 
the cells expressed high levels of active DDAH I enzyme 
from the pTRE2hyg.DDAHI vector, which in turn led to 
high l-citrulline production. In the presence of DOX, only 
endogenous DDAH I was expressed, whereas removal of 
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Fig. 1  In vitro characterization of C6 DDAH cells in comparison 
with parental cells. Cells were treated for 4 days with 2 µg/ml DOX. 
For the last 48  h, cells were also stimulated with cytokines (10  ng/
ml TNF-α, 1000 U/ml IFN-γ) and 5 µg/ml LPS. a iNOS (131 kDa) 
and c DDAH I (34 kDa) expression determined by western blot and 
integrated density of individual bands (corrected for loading). b NOx 
production. d l-citrulline production evaluated after 4-h incubation 
with ADMA substrate. Results are mean + 1 SEM of three separate 
experiments (*P < 0.05, **P < 0.01, ***P < 0.001)
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DOX led the overexpression of DDAH I, resulting in a five-
fold increase in activity (Fig. 1d; Table 1). Overexpression of 
DDAH I did not affect the growth properties of cells in vitro; 
cell proliferation and death over 5 days were the same in 
the presence or absence of DOX (Supplementary Fig. 1a, 
b). Cytokines and LPS had no effect on the expression of 
DDAH I by all three cell lines (Fig. 1c).
DDAH I up‑regulation in tumours does not affect 
growth rate when NO is absent
To investigate whether overexpression of DDAH I in 
tumours affects growth rate in the absence of NO, tumours 
derived from C6 DDAH cells were grown subcutane-
ously in mice and compared with constitutive DDAH I 
Fig. 2  In vivo characterization 
of C6 DDAH tumour xenografts 
compared with D27 tumour 
xenografts. C6 DDAH cells 
were pre-treated with 2 µg/
ml DOX in the medium for 5 
days (group A). Mice with C6 
DDAH tumours were given 
0.2 mg/ml DOX in 5% (w/v) 
sucrose or 5% (w/v) sucrose 
alone (n = 6 per group) in the 
drinking water ad libitum. Mice 
with D27 (C6 constitutively 
DDAH overexpressing) tumours 
were given drinking water alone 
(n = 4). a, b Example western 
blots of tumour homogenates 
and mean box plot distribu-
tions of the integrated densi-
ties of the individual bands 
for DDAH I (a) and iNOS 
(b) corrected using α-tubulin 
and α-actin respectively. c 
l-citrulline production and (d) 
NOx production by tumours, 
determined from homogenates. 
e TDTs in days. Results are the 
mean + 1 SEM of measurements 
made from all tumours in each 
group (*P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001, 
One-Way ANOVA with Bonfer-
roni’s multiple comparison 
post-test)
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overexpressing tumours (D27), in which the DDAH/
ADMA/NO pathway is fully functional. Results from 
mice with C6 DDAH tumours derived from cells pre-
treated for 5 days with DOX (group A) are presented in 
Fig. 2 together with results from mice with D27 tumours. 
Results from mice with C6 DDAH tumours derived from 
cells grown in normal medium without DOX (group B) 
were very similar to results from group A and therefore 
are presented in Supplementary Fig. 2. DDAH I protein 
expression in C6 DDAH (groups A and B) tumours in 
mice not given DOX in the drinking water was compara-
ble with expression in D27 tumours. However, addition 
of DOX in the drinking water was sufficient to “switch 
off” DDAH I overexpression in C6 DDAH tumours (both 
groups) returning to the low endogenous DDAH I expres-
sion levels (Fig. 2a, Supplementary Fig. 2a, Table 1). 
Production of l-citrulline, and hence DDAH enzymatic 
activity, was approximately five times higher in C6 DDAH 
tumours grown without DOX compared with those grown 
with DOX in both groups A and B (Fig. 2c, Supplemen-
tary Fig. 2b). Unexpectedly, D27 tumours had signifi-
cantly lower levels of DDAH activity (~ 18-fold) than C6 
DDAH − DOX tumours (group A) (Fig. 2c). Pre-treatment 
of the C6 DDAH cells with DOX prior to implantation 
(group A) had no effect on DDAH I activity. No significant 
differences were observed in the expression of iNOS or the 
production of NOx between C6 DDAH ± DOX tumours 
(group A) (Fig. 2b, d; Table 1). In contrast, NOx produc-
tion was significantly higher (threefold) in D27 tumours 
compared with the C6 DDAH ± DOX tumours (group 
A). DDAH I overexpression in the absence of NO had no 
effect on the growth rate of C6 DDAH tumours (group A) 
(Fig. 2e, Supplementary Fig. 1c). Pre-treating the cells 
with or without DOX also had no effect on the growth rate 
of C6 DDAH tumours (groups A and B) (Fig. 2e, Supple-
mentary Fig. 2c). All tumours grew with similar growth 
rates, with TDTs between 3 and 4 days.
DDAH I overexpression does not alter VEGF 
production when NO is limited
Having characterised the DDAH/ADMA/NO axis in the 
C6 DDAH cells and tumours, the effects of DDAH I over-
expression on VEGF were investigated. C6 DDAH ± DOX 
cells produced less VEGF than C6 wt and C6 par cells, and 
DDAH I overexpression in the C6 DDAH − DOX cells did 
not increase VEGF production (Fig. 3a; Table 1). Moreover, 
cytokine stimulation did not have an effect on VEGF pro-
duction in C6 wt, C6 par or C6 DDAH cells in the absence 
or presence of DOX. Interestingly, the presence of DOX 
increased VEGF production by 1.8-fold in C6 wt cells, 1.5-
fold in C6 par and 2.5-fold in C6 DDAH cells (Fig. 3a). 
In tumour homogenates, VEGF production was low in all 
C6 DDAH tumours (groups A and B) and no significant 
differences were found between tumours grown in the pres-
ence or absence of DOX (Fig. 3b, Supplementary Fig. 2d, 
Table 1). VEGF production was markedly higher (~ 26-fold) 
in D27 tumours compared with C6 DDAH ± DOX tumours 
(group A). Results for DDAH I expression, NO production 
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Fig. 3  Investigation of the effect of DDAH I on VEGF expression 
in  vitro and in  vivo. a VEGF levels in culture medium from cells 
treated with 2  µg/ml DOX for 6 days. For the last day, cells were 
also stimulated with cytokines (10 ng/ml TNF-α, 1000 U/ml IFN-γ) 
and 5 µg/ml LPS. Culture medium was collected from the last 24 h 
of treatment. b VEGF expression in tumour homogenates. C6 DDAH 
tumours (group A) derived from animals provided with drinking 
water containing 0.2  mg/ml DOX in 5% (w/v) sucrose or 5% (w/v) 
sucrose alone (n = 6 per group). Mice with D27 tumours were given 
drinking water alone (n = 4). Results are mean + 1 SEM of dupli-
cate measurements from three separate in vitro experiments or from 
all tumours in each group (*P < 0.05, ****P < 0.0001, One-Way 
ANOVA with Bonferroni’s multiple comparison post-test)
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and VEGF expression from all cell lines and tumours are 
briefly summarized in Table 1.
In the absence of NO tumour vascular development 
is unaffected by DDAH I up‑regulation
Non-invasive MRI was used to explore whether DDAH I 
overexpression in C6 DDAH tumours (groups A and B) 
caused any NO-independent effects on functional tumour 
vasculature in vivo. Representative  T2-weighted images 
and parametric maps of baseline  R2* and carbogen-induced 
ΔR2* (ΔR2*CB) from D27 and C6 DDAH ± DOX tumours 
(group A) are shown in Fig. 4a. Parametric maps of frac-
tional blood volume (fBV) are also shown for the C6 
DDAH ± DOX tumours (group A). No differences in base-
line R2* were found across the tumour groups (Fig. 4b, Sup-
plementary Fig. 2e). All mice physiologically responded to 
carbogen breathing with an increase in blood oxygen satura-
tion of 4 ± 1% across all groups. However, carbogen inhala-
tion induced a negligible change, approximately  −3.2 s−1, 
in mean tumour R2* in all cohorts (Fig. 4c, Supplementary 
Fig. 2f). C6 DDAH tumours typically exhibited a low fBV 
Fig. 4  The effects of DDAH I up-regulation on tumour vascular 
development as determined by MRI of C6 DDAH xenografts (group 
A). a Representative  T2-weighted images, parametric maps of base-
line R2*air, ΔR2*CB in response to carbogen and fractional blood vol-
ume (fBV) acquired from the central tumour slice. ROIs encompass-
ing the whole tumour volume are demarcated on the  T2-weighted 
images. Box plot distributions of the median R2*air (b) and ΔR2*CB 
(c) values measured over the whole tumour volume of D27 (n = 4) 
and C6 DDAH ± DOX (n = 6) xenografts. Median fBV values (d) and 
median ΔR2*CB values (e) in regions where fBV is higher than the 
median fBV value of all the data of C6 DDAH − DOX (n = 4) and C6 
DDAH + DOX (n = 3) tumours
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(less than 1.5%), and despite a trend towards higher fBV 
in the C6 DDAH + DOX tumours (group A), the difference 
was not significant (Fig. 4d). Application of a retrospec-
tive analysis, previously described in Papaevangelou et al. 
[22], to the ΔR2*CB maps, in which regions with vascular 
volume greater than the overall median of all the C6 DDAH 
tumours (fBV > 0.84%) were selected, the ΔR2*CB response 
was smaller in C6 DDAH tumours (group A) grown with-
out DOX compared to those grown with DOX, but this 
difference was not significant (Fig. 4e). No differences 
were observed between the baseline R2* measured during 
air breathing prior to carbogen challenge (R2*air) and that 
measured following resumption of air breathing prior to 
administration of USPIO particles (R2*pre−USPIO).
Ex vivo histological analysis was also used to assess the 
tumour vasculature. Representative histological images from 
D27 and C6 DDAH ± DOX (group A) tumours are shown in 
Fig. 5, and some higher magnification images are shown in 
Supplementary Fig. 3. Hoechst was found closer to the periph-
ery of the tumour where vessels were better perfused, whereas 
pimonidazole adducts were located closer to the tumour centre 
nearer to necrotic areas (Fig. 5a). More necrotic regions (indi-
cated with black arrows) were observed in D27 tumours com-
pared with C6 DDAH ± DOX (group A) tumours (Fig. 5b). 
Fig. 5  Histological assessment of the vasculature of C6 
DDAH ± DOX (group A) and D27 xenografts. a Representative com-
posite images from frozen whole C6 DDAH ± DOX tumour sections 
stained with the perfusion marker Hoechst 33342 (blue fluorescence) 
and the hypoxia marker pimonidazole (green fluorescence). b H&E-
stained frozen sections from C6 DDAH ± DOX and D27 tumours 
indicating necrotic regions (arrows). c Composite images from frozen 
C6 DDAH ± DOX and D27 tumour sections stained with the endothe-
lial cell marker CD31 (green fluorescence) and the perivascular cell 
marker α-SMA (red fluorescence). Scale bar is 1 mm
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Mature vessel smooth muscle cells and pericytes surrounded 
the endothelial cell layer (Fig. 5c). White arrows in the com-
posite images indicate large vessels where the localization of 
CD31 and α-SMA in the vessel wall is more profound (Sup-
plementary Fig. 3). DDAH I overexpression did not result in 
any differences in the degree of tumour perfusion (Hoechst 
perfused area) and hypoxia (pimonidazole adduct area) in the 
C6 DDAH ± DOX tumours (group A) (Fig. 6a, b). The extent 
of necrosis was significantly higher in D27 tumours compared 
with C6 DDAH ± DOX tumours (group A), whereas necrosis 
was similar in the C6 DDAH tumours (group A) independently 
of DDAH I expression levels (Figs. 5b, 6c). The endothelial 
cell content (CD31) of D27 tumours was significantly higher 
(3.3%) than in C6 DDAH tumours (group A), which had 
an endothelial cell content of 1.7% in both the absence and 
presence of DDAH I expression (Figs. 5c, 6d). D27 tumours 
had a significantly higher perivascular cell content (α-SMA, 
3%) compared with C6 DDAH ± DOX tumours (group A) 
(0.6%) (Figs. 5b, 6e). The fraction of mature vessels, quanti-
fied using the ratio of α-SMA stained area versus the CD31 
stained area, was also higher in D27 tumours compared with 
C6 DDAH ± DOX tumours (group A) (Fig. 6f). However, no 
differences were observed in the C6 DDAH tumours (group 
A) in the absence or presence of DOX for either CD31 or 
α-SMA staining.
Discussion
In this study, a novel tetracycline-inducible DDAH I 
overexpression system, in which DDAH I was overex-
pressed in the absence of DOX, was generated from nitric 
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oxide-deficient C6 parental cells, in order to investigate 
the direct, NO-independent role of DDAH I on tumour 
growth and angiogenesis. Our key findings indicate that 
in the absence of NO production, DDAH I overexpression 
had no effect on tumour growth, tumour vascular charac-
teristics as assessed by in vivo MRI, ex vivo quantifica-
tion of VEGF, vessel perfusion, hypoxia, endothelial and 
perivascular cell content, or necrosis.
Previous studies have shown that increased DDAH 
activity leads to degradation of the NOS inhibitors ADMA 
and l-NMMA, and therefore increases NO. This has been 
demonstrated in constitutive DDAH I overexpressing 
D27 cells and tumours, where increased DDAH I activ-
ity reduced ADMA concentration and resulted in a two-
fold increase in NO synthesis [5]. In our study, the DOX-
inducible C6 DDAH cells and tumours (groups A and B) 
exhibited very limited NO production independently of 
DOX, and therefore independently of DDAH I expression. 
D27 tumours produced a significantly higher concentration 
of NO compared with the C6 DDAH tumours (± DOX). 
Overexpression of DDAH I in D27 tumours led to faster 
growth rates compared with wild-type C6 tumours [5]. In 
our study, the growth rates of the NO-deficient C6 DDAH 
tumours (groups A and B) were independent of DDAH I 
overexpression. Hence, in light of our findings, we can 
deduce that the effect of DDAH on D27 tumour growth 
reported by Kostourou et al. [5] was NO-mediated. No 
significant differences were observed between the DOX-
treated and untreated C6 DDAH tumours in the MRI 
measures of fBV and carbogen-induced R2* changes or 
in the histologically assessed vessel perfusion, hypoxia, 
micro-vessel density and vessel maturation. This was prob-
ably due to the limited NO production in these tumours. 
However, in D27 tumours, where production of NO was 
significantly higher, perivascular cell coverage, and thus 
vessel maturation, were higher compared with the C6 
DDAH tumours (group A). DDAH I protein expression 
had no effect on the resulting degree of necrosis in C6 
DDAH tumours (group A), while D27 tumours, which 
had high NO production, were more necrotic. Previous 
studies have shown that high concentrations of NO can 
directly stimulate apoptosis or necrosis [27, 28]. In C6 
DDAH tumours, in the absence of NO, altering DDAH 
I expression in order to regulate ADMA did not have an 
effect on the vascular growth of those tumours. We can 
therefore conclude that DDAH I overexpression alone was 
not sufficient to overcome the effects of low NO produc-
tion on tumour growth and vascular development. This is 
in agreement with a previous study showing that antisense 
iNOS expressing and DDAH I overexpressing C6 tumours 
(referred to as ASD10) had similar growth rates and vessel 
perfusion compared with AS7 tumours (antisense iNOS 
expressing C6 tumours), and slower growth rates and 
lower perfusion than D27 (DDAH I overexpressing) and 
wild-type C6 tumours [29].
The DDAH I/ADMA pathway is known to regulate 
VEGF-induced angiogenesis in an NO-dependent manner 
[30, 31]. In the present study, VEGF expression was signifi-
cantly greater in D27 tumours compared with C6 DDAH 
tumours (groups A and B) and this correlated with increased 
NO production in D27 tumours. Increased VEGF expres-
sion in D27 tumours (DDAH I overexpressing C6 tumours) 
has previously been reported in vitro and in vivo [5]. This 
increased VEGF expression, downstream of an increase 
in NO production, was diminished in C6 tumours overex-
pressing a mutant inactive DDAH I enzyme [32]. However, 
ADMA and DDAH can also regulate VEGF expression via 
NO-independent mechanisms, such as via DDAH binding 
to protein kinase A (PKA) and subsequent phosphorylation 
of the transcription factor Sp1 [10]. In our study, DDAH 
I overexpression in C6 DDAH cells and tumours and NO 
accumulation in wild-type C6 cells did not have an effect 
on VEGF expression, suggesting that in C6 tumours VEGF 
production is not reliant only on the production of NO. This 
finding was supported by the fact that in both C6 DDAH and 
C6 parental cells VEGF was expressed despite the limited 
NO concentration. Yang et al. [33] suggested that in C6 cells 
VEGF expression was adjusted and maintained at a certain 
level according to factors, such as MMPs, HIF-1 and pH. 
Overall, our study and previous studies suggest that C6 cells 
can exert both NO-dependent and NO-independent regula-
tion of VEGF.
DOX led to an in vitro increase in VEGF in all cell lines 
in this study in the absence of cytokine stimulus. However, 
the effect was diminished in the presence of cytokine and 
LPS stimulus. Moreover, no similar effect of DOX on VEGF 
production was observed in the tumour microenvironment in 
the in vivo model. There are studies that have reported both 
positive and negative effects of DOX on VEGF and angio-
genesis; however, the mechanism of this interaction still 
remains elusive. A study in murine melanoma tumours has 
shown that doxycycline treatment increased VEGF expres-
sion in vivo, possibly due to aggravation of hypoxia [34]. On 
the contrary, Su et al. have shown that doxycycline inhibits 
VEGF-induced angiogenesis in vivo [35]. In our study, the 
effect of DOX on VEGF does not impinge on our major find-
ings, since this effect was only observed in vitro not in vivo 
and mainly in the absence of cytokine and LPS stimulus.
We observed that DDAH I activity was significantly 
lower in D27 tumours compared with C6 DDAH − DOX 
tumours (groups A and B), despite them having similar 
levels of DDAH I expression. Leiper et al. [36] have shown 
that in situations of oxidative or nitrosative stress, NO can 
inhibit bacterial DDAH enzymatic activity by reversible 
S-nitrosylation of the active-site cysteine (Cys249) of the 
Cys–His–Glu catalytic triad. This provides a homeostatic 
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mechanism to regulate NO; increased NO production 
reduces DDAH activity, which in turn leads to ADMA 
accumulation and inhibition of NOS, thereby restrain-
ing further NO production [36]. Therefore, the observa-
tions in the present study that D27 tumours showed (a) 
reduced DDAH activity, and (b) increased NO produc-
tion could be explained by this negative feedback loop in 
which NO controls DDAH activity. Kostourou et al. [5] 
have shown that DDAH activity, assessed by conversion 
of 14C-labelled l-NMMA to 14C-labelled citrulline, was 
high in D27 tumours, suggesting that the time point dur-
ing tumour growth at which DDAH activity is measured 
is of great importance. Thus, another explanation for the 
reduced DDAH activity in the D27 cells observed in the 
present study could be that at the time of tumour excision 
(the time point at which DDAH activity was assessed), the 
amount of DDAH enzyme required to metabolize all the 
available ADMA was being used, whereas the remainder 
unused enzyme became inactivated as it was not required.
We have now shown that in C6 gliomas in the absence 
of NO, endogenous DDAH I overexpression did not alter 
tumour growth or vascular development. Our data rein-
force the hypothesis that regulating DDAH I expression 
in gliomas by using a DDAH inhibitor could be a use-
ful anti-cancer therapeutic approach, as it could lead to 
indirect anti-tumour and anti-angiogenic effects by raising 
endogenous levels of ADMA leading to a subsequent inhi-
bition of NO synthesis. PD 404182, an irreversible inhibi-
tor of human DDAH I, has previously shown therapeutic 
potential in septic shock-induced vascular collapse. PD 
404182 led to ADMA-mediated reduction of NO and abro-
gated the formation of tube-like structures by endothelial 
cells in an in vitro angiogenesis assay [37]. Another potent 
inhibitor of human DDAH I, Cl-NIO, has been shown to 
decrease NO production in A375 melanoma cells [38]. 
Such inhibitors appear to be promising tools for the control 
of methylarginine-mediated NO and could be used as anti-
angiogenic therapeutic compounds in diseases where NO 
production is elevated, such as septic shock, or in diseases 
characterized by pathologically excessive angiogenesis, 
such as different types of cancer. Our study provides a 
rationale for developing novel DDAH inhibitors, such as 
arginine analogue 10a [39], to control NO biosynthesis 
and target tumour angiogenesis.
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